Cargando…
Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer
Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist ‘Smac mimetic’ compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced wit...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Biology Reports Ltd
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948278/ https://www.ncbi.nlm.nih.gov/pubmed/20948609 http://dx.doi.org/10.3410/B1-79 |